Business
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress
About this update from Novartis Ag
Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible urticaria, to be highlighted in late-breaker oral presentationNew Phase IIIb REMIXED extension data in chronic spontaneous urticaria to provide additional efficacy and safety data for RhapsidoPhase II Rhapsido food allergy dose-response analysis in adults with IgE-mediated peanut allergy also to be presentedBasel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, spanning Rhapsido® (remibrutinib) clinical trial results and real-world evidence on patient burden and treatment experience. Highlights include two late-breaking oral presentations; the Phase III RemIND trial for Rhapsido in chronic inducible urticaria (CIndU) and extension data from the Phase IIIb REMIXED trial in chronic spontaneous urticaria (CSU).“The Rhapsido presentations at EAACI 2026 expand our understanding of BTK inhibition across multiple immune-mediated diseases and provide evidence of its potential to make a meaningful impact for patients who continue to face significant burden and limited treatment options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “Novartis will present Rhapsido data from a long-term extension trial in chronic spontaneous urticaria, Phase III data in three types of chronic inducible urticaria, and early Phase II dose-response analysis for food allergy – together providing scientific evidence for its impact across numerous diseases.”Abstracts accepted by EAACI include: Molecule/Disease Abstract Title Abstract Number/Presentation Details Rhapsido®(remibrutinib) Chronic Spontaneous Urticaria/Chronic Inducible Urticaria Remibrutinib demonstrated superior efficacy vs placebo and favorable safety in patients with chronic inducible urticaria in the phase 3 REMIND study Abstract #L-OAS03Oral PresentationJune 12, 12:36 – 12:48pm TRT Remibrutinib demonstrated continuous efficacy and favorable safety in patients with chronic spontaneous urticaria in the randomized withdrawal period of the phase 3b REMIXED extension study Abstract #L-OAS03Oral PresentationJune 12, 12:48 – 1:00pm TRT Remibrutinib-induced decreases in B cell biomarkers are associated with complete and sustained response in chronic spontaneous urticaria patient...